11 results on '"Byhardt R"'
Search Results
2. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
- Author
-
Komaki R, Scott C, Lee JS, Urtasun RC, Byhardt RW, Emami B, Andras EJ, Asbell SO, Rotman M, and Cox JD
- Subjects
- Administration, Oral, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Antineoplastic Agents, Phytogenic administration & dosage, Antineoplastic Agents, Phytogenic adverse effects, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Body Surface Area, Carcinoma, Non-Small-Cell Lung radiotherapy, Cause of Death, Cisplatin administration & dosage, Cisplatin adverse effects, Clinical Trials, Phase III as Topic, Combined Modality Therapy, Disease Progression, Dose Fractionation, Radiation, Etoposide administration & dosage, Etoposide adverse effects, Female, Humans, Injections, Intravenous, Karnofsky Performance Status, Lung Neoplasms radiotherapy, Male, Middle Aged, Multivariate Analysis, Neoplasm Staging, Radiotherapy adverse effects, Radiotherapy Dosage, Remission Induction, Sex Factors, Survival Rate, Treatment Outcome, Vinblastine administration & dosage, Weight Loss, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy
- Abstract
A hyperfractionated radiation therapy (HFX RT) trial (1.2 Gy twice daily, b.i.d.) (HFX) for non-small cell lung cancer (NSCLC) showed that 69.6 Gy resulted in better survival than did lower total doses (Radiation Therapy Oncology Group, RTOG 83-11) and that cisplatin concurrent with irradiation improved local control and survival over RT alone (Radiation Therapy Oncology Group, RTOG 91-06). Concurrent combination chemotherapy and HFX could improve both local and systemic control. In a phase II trial (RTOG 91-06) for inoperable NSCLC, two cycles of PE were used [cisplatin 50 mg/m2 intravenously (i.v.) days 1 and 8, etoposide 50 mg orally (p.o.) b.i.d., 75 mg/day if body surface area (BSA) < 1.7 m2, days 1-14] starting on day 1 of HFX (69.6 Gy) and repeated on day 29. HFX/PE was compared with HFX (69.6 Gy) from an earlier phase II trial (RTOG 83-11). Seventy-six patients treated with HFX/PE and 203 patients who received HFX alone were compared for toxicity, response, survival, and patterns of failure. The rates of grade 4 nonhematologic toxicity were similar (3.0% for HFX/PE, 3.0% for HFX), but grade 4 hematologic toxicity occurred only with HFX/PE 56.6%. Three (3.9%) HFX/PE patients had fatal toxicity (2 pulmonary, 1 renal); 1 HFX patient had fatal esophageal toxicity. Response and metastasis rates were similar for the two treatments, but infield (p = 0.054) and overall (p = 0.04) progression-free survival rates were better with HFX/PE. Median survivals were 18.9 months with HFX/PE and 10.6 months with HFX. Two-year survival rates were 36% for HFX/PE and 22% for HFX (p = 0.014). The differences in survival between HFX/PE and HFX remained borderline statistically significant (p = 0.0593) in the multivariate model, which included weight loss, Karnofsky performance status (KPS), sex, and stage. HFX/PE is an effective regimen in patients with inoperable NSCLC, although it is considerably more toxic, and is undergoing a comparison in a three-arm randomized phase III study against induction cisplatin/vinblastine plus standard once-daily RT and against cisplatin/vinblastine concurrent with standard RT.
- Published
- 1997
- Full Text
- View/download PDF
3. Intraoperative radiation therapy of extrahepatic biliary carcinoma: a report of RTOG-8506.
- Author
-
Wolkov HB, Graves GM, Won M, Sause WT, Byhardt RW, and Hanks GE
- Subjects
- Adenocarcinoma surgery, Bile Duct Neoplasms surgery, Combined Modality Therapy, Gallbladder Neoplasms surgery, Humans, Intraoperative Period, Lymphatic Irradiation, Radiotherapy Dosage, Adenocarcinoma radiotherapy, Bile Duct Neoplasms radiotherapy, Gallbladder Neoplasms radiotherapy
- Abstract
Twenty-three patients with unresected, resected but residual, or locally recurrent biliary duct cancer were entered on a Radiation Therapy Oncology Group (RTOG) Phase I-II study. Of 16 patients who were properly entered and eligible for study, eight patients (50%) completed protocol treatment including intraoperative radiation therapy (IORT). Minor acute complications from therapy were common. There was no early grade 3 or 4 toxicity. Major long-term toxicity (grade 4) was noted in one patient who suffered a perforated viscous related to salvage radiation therapy for a scar recurrence and died of infection 1 month after retreatment. With a median follow up of 10.5 months, two of the eight patients who received IORT are alive. Of the six patients who died, one had persistent disease, one had the tumor recur in the surgical wound and subsequently died of complications related to retreatment with high dose radiation, and one died of intercurrent disease. In addition, two patients died with liver metastasis, and one died with intraabdominal disease outside of the IORT volume. Bulk of disease may be an important determinant of outcome.
- Published
- 1992
- Full Text
- View/download PDF
4. Phase II trial of combination chemotherapy and irradiation in non-small-cell lung cancer, Radiation Therapy Oncology Group 88-04.
- Author
-
Sause WT, Scott C, Taylor S, Byhardt RW, Banker FL, Thomson JW, Jones TK, Cooper JS, and Lindberg RD
- Subjects
- Aged, Animals, Carcinoma, Non-Small-Cell Lung pathology, Cisplatin administration & dosage, Combined Modality Therapy adverse effects, Drug Evaluation, Female, Humans, Lung Neoplasms pathology, Male, Middle Aged, Survival Analysis, Vinblastine administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung radiotherapy, Lung Neoplasms drug therapy, Lung Neoplasms radiotherapy
- Abstract
Encouraging results of several clinical trials utilizing combination chemotherapy and irradiation in unresectable non-small-cell lung cancer have been reported. A recent report from a cooperative group study suggested that preirradiation vinblastine and cisplatin improved survival over irradiation alone. In an attempt to enhance the possible effectiveness of combination chemotherapy and irradiation, the Radiation Therapy Oncology Group embarked on a Phase II trial utilizing preirradiation vinblastine (5 mg/m2 weekly x 5) and cisplatin (100 mg/m2) on days 1 and 29 prior to irradiation and on days 50, 71, and 92 during irradiation. The irradiation began on day 50 and consisted of 6300 cGy in 7 weeks. Between May 20, 1988 and May 1, 1989, 30 patients were entered on study. Seventy-two percent of patients had Karnofsky status greater than 90, and 76% had weight loss less than 5%. Forty-eight percent of the patients were younger than 60 years of age. Forty-five percent of the patients had Stage IIIA disease. Eighty-three percent of the patients received at least four courses of vinblastine, and 59% received at least four courses of cisplatin. Seventy-eight percent of the patients received at least 95% of the prescribed irradiation. The major toxicity was hematologic, and there were two fatal complications in the study group. The preliminary survival figures are encouraging. This combination of chemotherapy and irradiation appears to be tolerable and may merit further investigation.
- Published
- 1992
- Full Text
- View/download PDF
5. What is the lowest effective biologic dose for prophylactic cranial irradiation?
- Author
-
Komaki R, Byhardt RW, Anderson T, Libnoch JA, Cox JD, Hansen R, and Holoye PY
- Subjects
- Actuarial Analysis, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Brain Neoplasms prevention & control, Carcinoma, Squamous Cell drug therapy, Cyclophosphamide administration & dosage, Cyclophosphamide therapeutic use, Female, Humans, Lung Neoplasms drug therapy, Male, Methotrexate administration & dosage, Methotrexate therapeutic use, Middle Aged, Radiotherapy Dosage, Vincristine administration & dosage, Brain Neoplasms secondary, Carcinoma, Squamous Cell radiotherapy, Lung Neoplasms radiotherapy
- Abstract
Between January 1974 and September 1984, 327 consecutive patients with small cell carcinoma of the lung (SCCL) free of clinical and brain scan (radionuclide or computed tomography) evidence of brain metastasis were treated at the Medical College of Wisconsin Affiliated Hospitals. All patients received single agent chemotherapy, consisting of cyclophosphamide or methotrexate (1974-1975), or combination chemotherapy with cyclophosphamide, doxorubicin, and vincristine with or without methotrexate and leukovorin (1976-1984). Between January 1974 and December 1974, 82 patients were treated with chemotherapy without prophylactic cranial irradiation (PCI). Between 1978 and 1984, all patients received PCI during the first week after diagnosis, simultaneous with their first cycle of chemotherapy. Chest irradiation was given to the complete responders to the chemotherapy. During the first 31/3 years of the study with PCI (January 1978-May 1981), 51 patients received 30 Gray (Gy) in 10 fractions in 2 weeks and five of them (10%) developed brain metastasis. Thereafter, 25 Gy in 10 fractions was consistently administered for PCI. Six of 194 patients (3%) developed brain metastasis. The cumulative (time corrected) probability of brain metastasis was approximately 10% at 1 year and was similar for patients who received 25 Gy and those who received 30 Gy. Although detailed neuropsychological testing has not been performed, clinically apparent late sequelae that might be attributed to PCI have not been seen. Nonetheless, the dose fractionation regimen of 25 Gy in 10 fractions with combination chemotherapy, cyclophosphamide, doxorubicin (or methotrexate), and vincristine is as effective in eliminating subclinical metastasis to the brain. It can be recommended for future trials until more data become available about late sequelae of treatment of SCCL and the patient characteristics and treatment factors that may contribute.
- Published
- 1985
- Full Text
- View/download PDF
6. Extended-field radiation therapy for prostatic carcinoma with para-aortic lymph node metastasis.
- Author
-
Lawton CA, Glisch C, Byhardt RW, Sehring S, Hartz A, and Cox JD
- Subjects
- Adenocarcinoma mortality, Aged, Biopsy, Humans, Lymphatic Metastasis, Male, Middle Aged, Prospective Studies, Prostatic Neoplasms mortality, Radiotherapy adverse effects, Adenocarcinoma radiotherapy, Prostatic Neoplasms radiotherapy
- Abstract
The finding of involvement of para-aortic lymph nodes in patients with adenocarcinoma of the prostate has been considered so ominous that further therapy has often only been palliative. What is the proportion of patients with carcinoma of the prostate with regional metastasis limited to the infra-diaphragmatic lymph nodes who might be cured or at least offered long-term progression-free survival by aggressive treatment? From June 1970 through March 1983, 114 patients were treated with curative intent for adenocarcinoma of the prostate, clinical Stage III, at the Medical College of Wisconsin Affiliated Hospitals. Twenty-three of these patients had evidence of metastasis to the para-aortic lymph nodes. These patients were treated aggressively with external radiation therapy to the entire pelvis and para-aortic region. The median dose to the prostate was 70 Gy, the pelvis 54 Gy, and the para-aortic region 50 Gy. The median period of observation after treatment was 53.5 months. The actuarial survival was 90% at 5 years and progression-free survival was 73% at 5 years. The rate of major complications was 4.3%. Although the number of patients is small, the data suggest that extended field radiation therapy can result in prolonged progression-free survival and perhaps cure many patients with juxtaregional dissemination of adenocarcinoma of the prostate.
- Published
- 1986
- Full Text
- View/download PDF
7. The prognostic significance of histologic subtyping in small cell carcinoma of the lung.
- Author
-
Choi H, Byhardt RW, Clowry LJ, Almagro UA, Remeniuk E, Holoye PY, and Cox JD
- Subjects
- Carcinoma, Small Cell mortality, Carcinoma, Small Cell pathology, Female, Humans, Lung Neoplasms mortality, Lung Neoplasms pathology, Male, Neoplasm Metastasis, Prognosis, Retrospective Studies, Carcinoma, Small Cell classification, Lung Neoplasms classification
- Abstract
Previously untreated patients with small cell carcinoma of the lung (SCCL), who were treated at the Medical College of Wisconsin with combined chemotherapy and radiation therapy, were retrospectively subtyped according to the 1981 World Health Organization Lung Cancer Classification. Of 54 evaluated patients, 27 (50%) had "oat cell" subtype, 22 (41%) "intermediate cell" variety, and five (9%) were classified as "combined" type. There was no significant difference in response to therapy or median survival between the subtypes. In addition to the absence of prognostic significance among the subtypes, there were many technical factors affecting accuracy of subtyping, including tissue-crushing artifacts, size of biopsy materials, fixation of tissue samples, and variation of subtypes within the same biopsy. We conclude that subtyping of SCCL should not be construed as a prognostic tool or guideline to therapy. However, the recognition that SCCL may manifest in a variety of histologic patterns, some of which may be misinterpreted as a histology other than SCCL, is probably more important for choice of therapy and prognosis than the individual subtypes.
- Published
- 1984
- Full Text
- View/download PDF
8. The role of radiation therapy in the treatment of recurrent adult laryngeal papillomatosis.
- Author
-
Byhardt RW and Almagro U
- Subjects
- Carcinoma, Squamous Cell pathology, Humans, Laryngeal Neoplasms pathology, Male, Middle Aged, Neoplasm Recurrence, Local pathology, Papilloma pathology, Tracheotomy, Laryngeal Neoplasms radiotherapy, Neoplasm Recurrence, Local radiotherapy, Papilloma radiotherapy
- Abstract
Laryngeal papillomatosis is an uncommon condition in the adult, but it can be severe enough to require tracheostomy for obstructive changes following multiple recurrences, despite surgical local excisions and medical therapies. Few satisfactory treatments are available for such cases to restore both airway function and speech. Some patients may require laryngectomy for progressive dysfunction. The role of radiation therapy has been controversial, with some reports of malignant transformation following treatment. The authors describe two cases treated with irradiation, resulting in complete clearance of the lesions and return of airway and vocal function. Follow-up is given, and the available literature is reviewed.
- Published
- 1988
- Full Text
- View/download PDF
9. Multiagent chemotherapy, prophylactic neuraxis irradiation, and consolidative irradiation for small cell carcinoma of the lung.
- Author
-
Byhardt RW, Cox JD, Libnoch JA, Komaki R, Holoye PY, and Anderson T
- Subjects
- Actuarial Analysis, Aged, Brain Neoplasms prevention & control, Brain Neoplasms secondary, Carcinoma, Small Cell pathology, Carcinoma, Small Cell radiotherapy, Cervical Vertebrae, Combined Modality Therapy, Cyclophosphamide administration & dosage, Doxorubicin administration & dosage, Female, Humans, Lung Neoplasms pathology, Lung Neoplasms radiotherapy, Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Neoplasm Staging, Nervous System Neoplasms radiotherapy, Pilot Projects, Prognosis, Thorax, Vincristine administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Small Cell drug therapy, Lung Neoplasms drug therapy, Nervous System Neoplasms prevention & control
- Abstract
Between 6/81 and 6/83, 73 patients with small cell carcinoma of the lung were treated according to a prospective protocol in which cyclophosphamide, doxorubicin, and vincristine (CAV) were given concurrently with prophylactic craniocervical irradiation to the level of C5. Both limited and extensive disease patients with normal computed tomography of the brain received 25 Gy in 10 fractions in 2 weeks. Complete responders to CAV received consolidative thoracic irradiation (CTI) to the local-regional primary (37.5 Gy in 15 fractions in 3 weeks), the first 25 Gy in 10 fractions serving as prophylaxis of the C6 to T12 spinal cord. The neuraxis from L1 to S2 then received 25 Gy in 10 fractions in 2 weeks. Consolidative irradiation of localizable metastatic sites was given in extensive disease patients. Partial and nonresponders to CAV received 50-60 Gy in 5-6 weeks to local-regional disease. With a median followup of 29 months, survival was significantly better (p less than .01) in patients receiving CTI to the chest after complete response to CAV (both limited disease and extensive disease) than without CTI. Of 41 patients completing the protocol and without central nervous system (CNS) involvement at presentation, four (9%) failed initially in the CNS (two brain, two spinal axis); CNS failure was the cause of death in all four patients with no other sites of metastases at death in two of these. Failure to complete protocol treatment was due to disease progression during chemotherapy in 25/73 (34%) and chemotherapy related complications (three sepsis, one gastrointestinal bleed) in four of 73 (5.5%) patients. CTI and prophylactic neuraxis irradiation did not increase morbidity or result in mortality in the sequence utilized; prophylactic neuraxis irradiation appears to reduce the CNS relapse rate, and CTI benefits survival.
- Published
- 1985
- Full Text
- View/download PDF
10. Changes in the relative risk and sites of central nervous system metastasis with effective combined chemotherapy and radiation therapy for small cell carcinoma of the lung.
- Author
-
Komaki R, Cox JD, Holoye PY, and Byhardt RW
- Subjects
- Brain radiation effects, Brain Neoplasms secondary, Carcinoma, Small Cell drug therapy, Carcinoma, Small Cell radiotherapy, Drug Therapy, Combination, Humans, Lung Neoplasms drug therapy, Lung Neoplasms radiotherapy, Risk, Time Factors, Carcinoma, Small Cell therapy, Central Nervous System Diseases prevention & control, Lung Neoplasms therapy
- Abstract
Prolongation of survival of patients with small cell carcinoma of the lung with current effective systemic therapy has been accompanied by a marked increase in the frequency of relapse in the central nervous system (CNS). Prophylactic cranial irradiation (PCI) was shown to reduce the frequency of brain metastasis, but there was no increased short-term survival. Therefore, the necessity for PCI early in the course of treatment has been questioned, especially for patients with extensive disease. From January 1974 through March 1982, 205 patients with small cell carcinoma of the lung were treated at the Medical College of Wisconsin Affiliated Hospitals. None had clinical, radioisotopic, or computed tomographic evidence of brain metastasis. Eighty-two patients received radiotherapy and chemotherapy, but no PCI; 123 patients received combination chemotherapy and radiation therapy with PCI. The cumulative probability of brain metastasis without PCI was 36% at 12 months and 47% at 24 months; the probabilities were 6 and 10%, respectively with PCI. The 24-month probability of brain metastasis in patients with limited disease and no PCI was 45%; for those with extensive disease, it was 47%. No patient presented with extracranial central nervous system (ECNS) metastasis and no one without PCI developed it. Twelve patients who received PCI developed ECNS metastasis; the cumulative probabilities rose to 14% at 12 months and 22% at 24 months. The increased frequency of ECNS involvement has led to a phase I trial of PCI followed by six cycles of combination chemotherapy, without maintenance chemotherapy, followed by irradiation of the chest and spinal cord for patients with complete response.
- Published
- 1983
11. Characteristics of long-term survivors after treatment for inoperable carcinoma of the lung.
- Author
-
Komaki R, Cox JD, Hartz AJ, Byhardt RW, Perez-Tamayo C, Clowry L, Choi H, Wilson F, Lopes da Conceicao A, and Rangala N
- Subjects
- Combined Modality Therapy, Female, Humans, Lung Neoplasms mortality, Lymphatic Metastasis, Male, Radiotherapy, High-Energy, Time Factors, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lung Neoplasms therapy
- Abstract
Between January, 1971 and August, 1978, 410 patients with histologically or cytologically confirmed inoperable or unresectable carcinoma of the lung of all cell types were treated with curative intent. Forty-five patients lived a minimum of 3 years and 32 patients lived 5 or more years. The 3-year survival rate increased from 7.6% (15/197) between January, 1971 and June, 1975 to 14.1% (30/213) for the interval from July, 1975 to August, 1978 (p less than 0.01). Factors associated with long-term survival were performance status (p less than 0.01), early stage (p less than 0.001), high total dose of radiation (p less than 0.02), large cell carcinoma (p less than 0.01), inoperable for medical reasons (p less than 0.001), and thoracotomy to determine unresectability (p less than 0.04). The difference in survival rates between the two time periods was not related to different patient factors. Survival rates were most improved in the second time period for patients with Stage II or Stage III carcinoma of the lung. Eight patients died from cancer between 36 and 54 months of initial treatment. Five patients died of intercurrent disease without evidence of cancer of the lung after 3 years. An increasing proportion of long-term survivors of inoperable carcinoma of the lung can be expected to result from a better understanding of these diseases, more technically sophisticated external irradiation, and the use of combination chemotherapy for small cell carcinoma.
- Published
- 1985
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.